Abstract: Background In type 2 diabetes, metformin reduces cardiovascular risk beyond the effect of glycaemic control. Since oxidative stress and the consequent enhanced platelet activation contribute to accelerated atherosclerosis in diabetes, we hypothesized that metformin could reduce oxidative stress in this condition. Methods We randomized 26 newly diagnosed type 2 diabetic subjects to assume either metformin (M, n = 13) or gliclazide (G, n = 13) for 12 weeks. Drugs were titrated as needed to achieve good glycaemic control. Before and after treatment, we determined blood glucose, insulin, HbA(1c), vitamin A and E levels and 8-iso-PGF(2 alpha), and 11-dehydro-thromboxane B-2 urinary excretion, an in vivo oxidative stress and a thromboxane-dependent platelet activation marker, respectively. Results Notwithstanding a comparable improvement in metabolic control, 8-iso-PGF(2 alpha) (M from 708 +/- 32 to 589 +/- 45 pg/mg cr, p < 0.001; G from 646 +/- 80 to 665 +/- 79, pg/mg cr, p = ns) and 11-dehydro-thromboxane B-2 (M from 2190 +/- 196 to 1753 +/- 150 pg/mg cr, p < 0.05; G from 2048 +/- 202 to 1923 +/- 223, pg/mg cr, p = ns) urinary excretion decreased after metformin but not after gliclazide treatment. After metformin, vitamin A and E levels significantly increased while they remained unchanged after gliclazide. Conclusions These data suggest that metformin could improve oxidative stress, preserve antioxidant function and restrain platelet activation in type 2 diabetes.

Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetes subjects

FORMOSO, Gloria;MICHETTI, NOEMI;DI FULVIO, PATRIZIA;PANDOLFI, Assunta;BUCCIARELLI T;CIABATTONI, Giovanni;DAVI', Giovanni;CONSOLI, Agostino
2008-01-01

Abstract

Abstract: Background In type 2 diabetes, metformin reduces cardiovascular risk beyond the effect of glycaemic control. Since oxidative stress and the consequent enhanced platelet activation contribute to accelerated atherosclerosis in diabetes, we hypothesized that metformin could reduce oxidative stress in this condition. Methods We randomized 26 newly diagnosed type 2 diabetic subjects to assume either metformin (M, n = 13) or gliclazide (G, n = 13) for 12 weeks. Drugs were titrated as needed to achieve good glycaemic control. Before and after treatment, we determined blood glucose, insulin, HbA(1c), vitamin A and E levels and 8-iso-PGF(2 alpha), and 11-dehydro-thromboxane B-2 urinary excretion, an in vivo oxidative stress and a thromboxane-dependent platelet activation marker, respectively. Results Notwithstanding a comparable improvement in metabolic control, 8-iso-PGF(2 alpha) (M from 708 +/- 32 to 589 +/- 45 pg/mg cr, p < 0.001; G from 646 +/- 80 to 665 +/- 79, pg/mg cr, p = ns) and 11-dehydro-thromboxane B-2 (M from 2190 +/- 196 to 1753 +/- 150 pg/mg cr, p < 0.05; G from 2048 +/- 202 to 1923 +/- 223, pg/mg cr, p = ns) urinary excretion decreased after metformin but not after gliclazide treatment. After metformin, vitamin A and E levels significantly increased while they remained unchanged after gliclazide. Conclusions These data suggest that metformin could improve oxidative stress, preserve antioxidant function and restrain platelet activation in type 2 diabetes.
File in questo prodotto:
File Dimensione Formato  
Formoso_et_al-2008-Diabetes-Metabolism_Research_and_Reviews.pdf

Solo gestori archivio

Tipologia: PDF editoriale
Dimensione 186.75 kB
Formato Adobe PDF
186.75 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11564/133206
Citazioni
  • ???jsp.display-item.citation.pmc??? 24
  • Scopus 59
  • ???jsp.display-item.citation.isi??? 57
social impact